Published on 30 Mar 2023 on Simply Wall St. via Yahoo Finance
When Will Acasti Pharma Inc. (NASDAQ:ACST) Turn A Profit?
With the business potentially at an important milestone, we thought we'd take a closer look at Acasti Pharma Inc.'s (NASDAQ:ACST) future prospects. Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. With the latest financial year loss of US$9.8m and a trailing-twelve-month loss of US$17m, the US$19m market-cap company amplified its loss by moving further away from its breakeven target. As path to profitability is the topic on Acasti Pharma's investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.
See our latest analysis for Acasti Pharma
Acasti Pharma is bordering on breakeven, according to the 3 American Pharmaceuticals analysts. They expect the company to post a final loss in 2023, before turning a profit of US$161m in 2024. So, the company is predicted to breakeven just over a year from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of -28% is expected,